Sign In
Buy FBIOP
$20.77
+0.340 (+1.66%)
At Close: Jun 03, 2026
Fortress Biotech: Is It Time To Pay The Deferred Preferred Stock Dividends?
05:20pm, Friday, 29'th May 2026
Fortress Biotech now holds $256 million in cash and only $39 million in debt, establishing a fortress balance sheet. FBIO's recent windfall from the Menkes disease drug sale positions it to easily pay
Fortress Biotech to Participate in A.G.P.'s Annual Virtual Healthcare Conference
08:30am, Monday, 18'th May 2026
MIAMI, May 18, 2026 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”), an innovative biopharmaceutical company focused on acquiring and advancing assets to enhance long-term v
Fortress Biotech Reports First Quarter 2026 Financial Results and Recent Corporate Highlights
04:10pm, Thursday, 14'th May 2026
ZYCUBO® approved by FDA to treat Menkes disease in the United States; Fortress subsidiary Cyprium Therapeutics closed the sale of its Rare Pediatric Disease Priority Review Voucher (PRV) for $205 mil
Fortress Biotech to Participate in the H.C. Wainwright 2nd Annual Royalty Company Virtual Conference
08:30am, Monday, 04'th May 2026
MIAMI, May 04, 2026 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”), an innovative biopharmaceutical company focused on acquiring and advancing assets to enhance long-term v
Fortress Biotech Reports 2025 Financial Results and Recent Corporate Highlights
04:05pm, Tuesday, 31'st Mar 2026
ZYCUBO® approved by FDA to treat Menkes disease in the United States; Fortress subsidiary Cyprium Therapeutics sold its Rare Pediatric Disease Priority Review Voucher (PRV) for gross proceeds of $205
Fortress Biotech (NASDAQ:FBIOP) Stock Price Up 22.9% – Here’s What Happened
02:58am, Tuesday, 24'th Feb 2026
Fortress Biotech, Inc. (NASDAQ: FBIOP - Get Free Report)'s share price rose 22.9% during mid-day trading on Monday. The stock traded as high as $13.79 and last traded at $13.52. Approximately 205,100
MIAMI, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”) and its majority-owned subsidiary, Cyprium Therapeutics, Inc. (“Cyprium”), today announced that Cypr
MIAMI, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”) and its majority-owned subsidiary, Cyprium Therapeutics, Inc. (“Cyprium”), today announced that Cypr
Rare Pediatric Disease Priority Review Voucher (PRV) granted by FDA at approval to be transferred from Sentynl Therapeutics to Cyprium
Fortress Biotech Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights
08:30am, Friday, 14'th Nov 2025
Total net revenue increased 20.5% to $17.6 million for third quarter of 2025 compared to the third quarter of 2024 Fortress subsidiary Checkpoint Therapeutics acquired by Sun Pharma; Fortress received
Fortress Biotech, Inc. (FBIO) Q3 2025 Earnings Call Transcript
10:41pm, Wednesday, 12'th Nov 2025
Fortress Biotech, Inc. ( FBIO ) Q3 2025 Earnings Call November 12, 2025 4:30 PM EST Company Participants Jaclyn Jaffe - Senior Director of Corporate Operations Claude Maraoui - Founder, President, CEO
Fortress Biotech (NASDAQ:FBIOP) Stock Price Down 1.9% – Time to Sell?
02:49am, Tuesday, 04'th Nov 2025
Fortress Biotech, Inc. (NASDAQ: FBIOP - Get Free Report)'s share price was down 1.9% during mid-day trading on Monday. The stock traded as low as $6.80 and last traded at $6.87. Approximately 7,918 sh
MIAMI, Oct. 21, 2025 (GLOBE NEWSWIRE) -- Urica Therapeutics, Inc. (“Urica” or the “Company”), a Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”) subsidiary, today announced that Crystaly
Fortress Biotech and Subsidiary Urica Therapeutics Announce Crystalys Therapeutics' $205 Million Series A Financing
08:05am, Wednesday, 01'st Oct 2025
Dotinurad is a next-generation URAT1 inhibitor in two Phase 3 clinical trials with potential for best-in-class safety and efficacy
Fortress Biotech and Cyprium Therapeutics Announce an Update on the NDA for CUTX-101
08:00am, Wednesday, 01'st Oct 2025
MIAMI, Oct. 01, 2025 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”) and its majority-owned subsidiary, Cyprium Therapeutics, Inc. (“Cyprium”), today announced that the
